Monoclonal gammopathy of uncertain significance
diseaseOn this page
Also known as benign monoclonal gammopathyMGUSmonoclonal gammopathy of undetermined significancemonoclonal gammopathy Of undetermined significance (MGUS)monoclonal gammopathy of undetermined significance (morphologic abnormality)monoclonal gammopathy of unknown significancemonoclonal gammopathy, benign
Summary
Monoclonal gammopathy of uncertain significance (MONDO:0004225) is a disease and 60 clinical trials. Top therapeutic interventions include celecoxib, fludeoxyglucose f 18, and hyaluronidase (human recombinant). A subtype of monoclonal gammopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 60
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | monoclonal gammopathy of uncertain significance |
| Mondo ID | MONDO:0004225 |
| MeSH | D008998 |
| DOID | DOID:7442 |
| NCIT | C3996 |
| SNOMED CT | 277577000, 58648008 |
| UMLS | C0026470 |
| MedGen | 44485 |
| GARD | 0007034 |
| Is cancer (heuristic) | no |
Also known as: benign monoclonal gammopathy · MGUS · monoclonal gammopathy of undetermined significance · monoclonal gammopathy Of undetermined significance (MGUS) · monoclonal gammopathy of undetermined significance (MGUS) · monoclonal gammopathy of undetermined significance (morphologic abnormality) · monoclonal gammopathy of unknown significance · monoclonal gammopathy, benign
Data availability: 2 cell lines.
Disease family
This is a subtype of monoclonal gammopathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › hematologic disorder › monoclonal gammopathy › monoclonal gammopathy of uncertain significance
Related subtypes (2): monoclonal paraproteinemia disease, acquired monoclonal Ig light chain-associated Fanconi syndrome
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 60.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 45 |
| PHASE2 | 11 |
| PHASE1 | 4 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04850846 | PHASE2 | ACTIVE_NOT_RECRUITING | Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma |
| NCT05939037 | PHASE2 | ACTIVE_NOT_RECRUITING | Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy |
| NCT06140524 | PHASE2 | RECRUITING | A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma |
| NCT00099047 | PHASE2 | COMPLETED | Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma |
| NCT00899353 | PHASE2 | TERMINATED | Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) |
| NCT01237054 | PHASE2 | COMPLETED | Imaging in MGUS, SMM and MM |
| NCT01571726 | PHASE2 | WITHDRAWN | Imaging Studies and the Development of Multiple Myeloma |
| NCT02566265 | PHASE2 | COMPLETED | Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients |
| NCT04731844 | PHASE2 | COMPLETED | Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer |
| NCT05114109 | PHASE2 | UNKNOWN | Isatuximab in Type I Cryoglobulinemia |
| NCT06046287 | PHASE2 | WITHDRAWN | Daratumumab for Polyneuropathy Associated With MGUS |
| NCT00025415 | PHASE1 | COMPLETED | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
| NCT01219010 | PHASE1 | COMPLETED | A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma |
| NCT01588015 | PHASE1 | COMPLETED | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
| NCT04439006 | PHASE1 | COMPLETED | Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization |
| NCT01408225 | Not specified | RECRUITING | Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource |
| NCT02269592 | Not specified | RECRUITING | Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome |
| NCT02726750 | Not specified | RECRUITING | Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma |
| NCT03327597 | Not specified | ACTIVE_NOT_RECRUITING | Iceland Screens, Treats or Prevents Multiple Myeloma |
| NCT04114084 | Not specified | RECRUITING | Sleep Apnea in Patients With MGUS and MM |
| NCT04702932 | Not specified | NOT_YET_RECRUITING | Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies |
| NCT04920084 | Not specified | ACTIVE_NOT_RECRUITING | A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) |
| NCT05136807 | Not specified | RECRUITING | Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies |
| NCT05283993 | Not specified | RECRUITING | A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH |
| NCT05361694 | Not specified | RECRUITING | Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions |
| NCT05539079 | Not specified | RECRUITING | A Prospective Long-term Observational Study in Patients With Monoclonal Gammopathy of Undetermined Significance |
| NCT05640843 | Not specified | RECRUITING | A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) |
| NCT05831358 | Not specified | ACTIVE_NOT_RECRUITING | Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program |
| NCT05965115 | Not specified | RECRUITING | The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study |
| NCT05969821 | Not specified | NOT_YET_RECRUITING | Clonal Hematopoiesis of Immunological Significance |
| NCT06055894 | Not specified | RECRUITING | A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS) |
| NCT06237803 | Not specified | RECRUITING | European Myeloma Network (EMN) Sample Project |
| NCT06383143 | Not specified | RECRUITING | Promoting Diagnosis and Management of AL in Italy (ProDigALIty) |
| NCT06472830 | Not specified | ENROLLING_BY_INVITATION | MGUS/MM Awareness and Genetics Insights Campaign (MAGIC) Screening Study |
| NCT06489613 | Not specified | NOT_YET_RECRUITING | Screening for Monoclonal Gammopathy in Individuals Undergoing Physical Examinations Using iMS-LC Assay Technology. |
| NCT06539832 | Not specified | RECRUITING | Intestinal Flora and Immunity in Monoclonal Gammopathy Patients |
| NCT06559033 | Not specified | NOT_YET_RECRUITING | Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS |
| NCT06644625 | Not specified | RECRUITING | CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study |
| NCT06690593 | Not specified | RECRUITING | Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy |
| NCT06895291 | Not specified | RECRUITING | Whole Body MRI in Oncology |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CELECOXIB | 4 | 1 |
| FLUDEOXYGLUCOSE F 18 | 4 | 1 |
| HYALURONIDASE (HUMAN RECOMBINANT) | 4 | 1 |
| ISATUXIMAB | 4 | 1 |
| SILTUXIMAB | 4 | 1 |
| ZANUBRUTINIB | 4 | 1 |
| LINVOSELTAMAB | 3 | 1 |
| FLUCICLATIDE | 2 | 1 |
| METFORMIN XR | 0 | 2 |
| CHEMBL5193128 | 0 | 1 |